December 10, 2024 4:38pm

As I wrote Monday, “momentum mania creates a soon to be a cratering sector; when I see highs, I contemplate bye”

News: UniQure (QURE +$8.01 or 109.73% to $15.30) after reaching a testing agreement with the FDA for its gene therapy Huntington's disease treatment called AMT-130 in patients. Huntington disease is a genetic brain disorder that causes nerve cells to break down. QURE could snag an accelerated approval if AMT-130 shows a benefit on Huntington's improvement on a scale called the composite Unified Huntington's Disease Rating Scale, or cUHDRS.

it’s not hard to be right so often, it’s about defining insight and dissecting sentiment

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

Invest like you're driving on an icy, windy road, not an open highway.

 

RegMed Investors’ (RMi) pre-open: everything’s relevant … https://www.regmedinvestors.com/articles/13728   

 

Tuesday: The Dow closed DOWN -154.10 points or -0.35%, the S&P closed DOWN -17.94 points or -0.30% while the Nasdaq closed DOWN -49.45 points or -0.25%

  • Trading digests a year-end rally of record levels

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • Waiting for U.S. inflation data set for release this week; economists forecast that headline inflation will rise +0.3% in November and +2.7% over the prior 12 months

Tuesday’s advance/decline line at the open was negative with 15 incliners, 18 declined and 2 flats; ending with a negative close at the close of 14 incliner, 18 decliners and 3 flats

  • The sentiment and sector churn continues

Metrics:  Tuesday, the IBB was down -1.18%, the XBI was down -0.82% while the VIX was up +0.03 points or +0.21% at 14.22

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”: 

Q4/24 – 2 positive and 5 negative closes

  • November – 1 holiday, 10 negative and 10 positive closes           
  • October: 8 positive and 15 negative sessions

52-week low:

  • Generation Bio (GBIO) closed at $1.21

 

Tuesday’s Closing Down (10 of 18):

  • Moderna (MRNA -$4.14 after Monday’s +$1.21)
  • Alnylam Pharmaceuticals (ALNY -$1.98 after Monday’s -$0.37),
  • CRISPR Therapeutics (CRSP -$1.16 after Monday’s -$2.49),
  • Verve Therapeutics (VERV -$0.47 after Monday’s +$0.72),
  • Fate Therapeutics (FATE -$0.44 after Monday’s +$0.07),
  • Regenxbio (RGNX -$0.41 after Monday’s +$0.59),
  • Ionis Pharmaceuticals (IONS -$0.32 after Monday’s +$0.47),
  • Ultragenyx Pharmaceuticals (RARE -$0.23)
  • Voyager Therapeutics (VYGR -$0.18 after Monday’s -$0.08)
  • Agenus (AGEN -$0.145),

Flat (3)

  • Harvard Apparatus RT (OTCQB: HRGN)
  • Homology Medicine (FIXX)
  • Prime Medicine (PRME)

Tuesday’s Closing Up (10 of 14):

  • uniQure NV (QURE +$8.01 after Monday’s -$0.15),
  • Beam Therapeutics (BEAM +$2.69 after Monday’s +$0.81),
  • Vericel VCEL +$1.20),
  • Lenz Therapeutics (LENZ +$0.86 after Monday’s -$3.85),
  • Blueprint Medicine (BPMC +$0.82 after Monday’s -$1.40),
  • Mesoblast (MESO +$0.36 after Monday’s -$0.26),
  • MiMedx (MDXG +$0.18 after Monday’s -$0.11),
  • AxoGen (AXGN +$0.17 after Monday’s -$0.24),
  • Compass Therapeutics (CMPX +$0.13)
  • Intellia Therapeutics (NTLA +$0.10 after Monday’s -$0.10),

 

The BOTTOM LINE: Cell and gene therapy stocks wavered on Tuesday as investors tread carefully on the eve of a closely watched consumer inflation report seen as key to the path of interest rates.

NOT much has changed, as I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”

The cell and gene therapy sector stocks kicked off December, the final month of 2024 with

  • A new week, starts with 2 negative closes
  • A Monday positive followed by Thursday and Wednesday, Tuesday’s negative closes and Friday positive close

The next test for indexes and stocks comes in a consumer inflation report, which will set the stage for the Fed's final interest rate decision of the year.

 

December is traditionally a good month for stocks, yet I see the sector range-bound and taking some hits into the end of 2024.

  • Never forget end of year tax selling and portfolio rotation due to recommendations are a’comin’!
  • Portfolio managers are addressing rotations as year comes to years-end.
  • I keep writing about uncertainty and skepticism … and coming realities.
  • Even with the potential for some market hiccups along the way, the good news is Q4 has historically skewed positively, even after sector earnings kicked the bucket down the road!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:    

  • Tuesday: uniQure NV (QURE), Beam Therapeutics (BEAM) and Blueprint Medicine (BPMC)
  • Monday: Moderna (MRNA), Verve Therapeutics (VERV) and Beam Therapeutics (BEAM)

The worst three (3) in the session: 

  • Tuesday: Moderna (MRNA), Alnylam Pharmaceuticals (ALNY) and CRISPR Therapeutics (CRSP)
  • Monday: Lenz Therapeutics (LENZ), CRISPR Therapeutics (CRSP) and Blueprint Medicine (BPMC)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.